DermaRite Industries Recalls DermaFungal Cream Over CGMP Deviation and Contamination Risk
DermaRite Industries, LLC has initiated a nationwide Class II recall (D-0162-2026) for its DermaFungal Antifungal Cream containing 2% Miconazole Nitrate. The recall, impacting 1,480 packets, stems from a Current Good Manufacturing Practice (CGMP) deviation at its North Bergen, NJ facility, where other products were found contaminated. This event underscores critical supply chain vulnerabilities for procurement and regulatory teams sourcing topical antifungal agents, necessitating immediate risk assessment and potential diversification strategies to mitigate disruption.
FDA-Initiated Recall: DermaRite Industries' CGMP Deviation for DermaFungal
DermaRite Industries, LLC, based in North Bergen, NJ, has initiated a Class II voluntary recall, designated D-0162-2026, for its DermaFungal Antifungal Cream with 2% Miconazole Nitrate. This critical action, initiated on August 27, 2025, impacts all lots of the product expiring on or before August 2027. The affected product is distributed nationwide across the USA, specifically 1,480 packets of the 5g (0.18 oz) size (NDC 61924-234-05), alongside the 106g (3.75 oz.) tubes (NDC 61924-234-04). The core reason for this recall is a significant Current Good Manufacturing Practice (CGMP) deviation. Specifically, the product was manufactured at a facility where other products and lots were identified as contaminated. For procurement directors, this means an immediate need to quarantine and return affected inventory, while regulatory affairs heads must document the recall process and assess the compliance breach. Supply chain VPs face potential disruption in the availability of this specific Miconazole Nitrate formulation, necessitating rapid inventory assessment and contingency planning.
Supply Chain Exposure and Risk for Topical Antifungal Formulations
The contamination issue at DermaRite Industries' North Bergen facility highlights a critical vulnerability within the supply chain for topical pharmaceutical products, particularly antifungal creams like DermaFungal. A Class II recall, while not the most severe, still indicates that the use of the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. The underlying CGMP deviation leading to contamination suggests systemic quality control failures. For procurement teams, this necessitates a rigorous re-evaluation of supplier audit protocols, especially for contract manufacturing organizations (CMOs) or primary manufacturers of active pharmaceutical ingredients (APIs) and finished drug products. Supply chain VPs must identify their exposure to DermaRite products and Miconazole Nitrate formulations from this specific facility. Business development executives should recognize the potential for market disruption and the need for robust alternative sourcing strategies to mitigate future supply shocks in the topical antifungal segment.
Broader Regulatory Scrutiny and Compliance Imperatives
This DermaRite recall occurs within an environment of heightened FDA scrutiny on manufacturing quality across the life sciences sector. Recent parallel events, such as Essential Wellness Pharma's Class II recall of Progesterone Injection due to sterility assurance failures in June 2026, and the FDA hearing concerning Amgen's Tavneos market future, underscore the agency's unyielding focus on product integrity and compliance. While these events are distinct from DermaRite's specific issue, they collectively signal a zero-tolerance approach to manufacturing deficiencies. Regulatory affairs heads must interpret this as a clear directive to bolster their internal quality systems, ensuring comprehensive CGMP adherence across all manufacturing sites, whether internal or external. Proactive investment in quality assurance, robust change control, and continuous monitoring of manufacturing processes are no longer optional but essential to avoid costly recalls, reputational damage, and potential enforcement actions.
Strategic Response to Mitigate Business Disruption
Given the ongoing nature of this recall, senior decision-makers must implement immediate and strategic responses. Procurement directors should prioritize verifying their inventory against the specified NDC codes (61924-234-05 for 5g packets, 61924-234-04 for 106g tubes) and expiry dates (all lots on or before 08/2027) to ensure full compliance with the recall D-0162-2026. Supply chain VPs need to engage directly with DermaRite Industries for detailed disposition instructions and to understand the root cause analysis and corrective actions being implemented at the North Bergen, NJ facility. While specific alternative suppliers for Miconazole Nitrate cream are not provided in the available intelligence, the imperative for diversification is clear. Regulatory affairs heads should review their entire portfolio of topical antifungal suppliers, initiating enhanced audits where necessary to preempt similar CGMP deviations. This proactive stance is crucial for maintaining market supply, safeguarding patient trust, and protecting long-term business continuity.